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There are a growing number of cases detailing acute hepatic necrosis in patients taking black cohosh (Cimicifuga racemosa), an
over-the-counter herbal supplement for management of menopausal symptoms. Our aim is to illustrate two cases of liver injury
following the use of black cohosh characterized by histopathological features mimicking autoimmune hepatitis. Both patients
reported black cohosh use for at least six months and had no evidence of another cause of liver disease. Their liver biopsies
showed a component of centrilobular necrosis consistent with severe drug-induced liver injury. In addition, the biopsies showed
characteristics of autoimmune-like liver injury with an interface hepatitis dominated by plasma cells. Although serum markers for
autoimmunehepatitiswerenotparticularlyelevated,bothpatientsrespondedtocorticosteroids,supportinganimmune-mediated
component to the liver injury. Liver injury following the use of black cohosh should be included in the list of diﬀerential diagnoses
for chronic hepatitis with features mimicking autoimmune hepatitis.
Copyright © 2009 Grace Guzman et al.ThisisanopenaccessarticledistributedundertheCreativeCommonsAttributionLicense,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1.Introduction
Black cohosh (Cimicifuga racemosa) is an herbal supplement
that is sold over-the-counter for management of menopausal
symptoms, menstrual irregularities, and arthritis. There are
now a number of manuscripts indicating liver injury from
black cohosh [1–7]. Here, we present two patients who
developed a drug-induced liver injury following the use of
black cohosh characterized by centrilobular necrosis and
histologic features mimicking autoimmune hepatitis (AIH)
who improved with corticosteroid therapy.
2. CaseStudies
The case series was approved by the Institutional Review
Board at the University of Illinois at Chicago.
Case 1. A 42-year-old woman presented to her primary care
provider with a two-month history of progressive malaise,
nausea, vomiting, and dizziness. On physical examination,
she had mild icterus and no stigmata of chronic liver disease.
Her only comorbidity was hypothyroidism. Her medications
included black cohosh, which she was taking for 6 months,
and levothyroxine 0.05mg daily. She discontinued black
cohoshwhenhersymptomsbegan.Shehadnofamilyhistory
of liver or autoimmune disease. She denied any alcohol or
drug use. Her total bilirubin level was 3.1mg/dL (normal
0.8–1.2), alanine transaminase (ALT) 1457U/L (normal 5–
40), aspartate transaminase (AST) 696U/L (normal 10–40),
alkaline phosphatase (ALP) 94U/L (normal 30–120U/L),
and international normalized ratio (INR) 1.2 (normal 0.8–
1.2). Further laboratories showed no serological evidence
of active hepatitis A, B, or C infection. Serological titers
for acute cytomegalovirus (CMV) and Epstein Barr virus
(EBV) were negative. Antinuclear antibody (ANA) was 1 :
40 and smooth muscle antibody was modestly elevated at 1
: 80. Serum iron was 169µg/dL (normal: 50 to 170µg/dL for
women), ferritin was 642ng/dL (normal: 15–200ng/mL for
females), and hemochromatosis gene analysis was negative.
Ceruloplasmin was in the normal range.2 Case Reports in Medicine
(a) (b)
Figure 1: This liver biopsy from Case 1 displays chronic hepatitis
remarkable for its dense interface activity with cholangiolar prolif-
eration (1a) (×200) and sheets of plasma cells and apoptosis (1b)
(×600).
Four months after her initial presentation, the liver
enzymes remained elevated with an ALT of 334U/L, AST
229U/L, and a total bilirubin of 1.4mg/dL. A liver biopsy
was performed which prompted a referral to the liver
center at the University of Illinois. The liver biopsy was
remarkable for necrosis around terminal hepatic venules,
lobular disarray, mild ballooning, apoptosis, Kupﬀer cell
reactivity, mild cholangiolar proliferation, and interface hep-
atitis remarkable for numerous plasma cells and eosinophils.
A repeat antismooth muscle antibody was normal at 1 : 20.
Prednisone treatment was initiated. A follow-up liver biopsy
was performed after three months. At this time, the liver
histology demonstrated chronic hepatitis with ﬁbroinﬂam-
matory expansion of portal tracts by moderate plasma cell
rich interface hepatitis, rare periportal hepatocyte apoptosis,
and mild cholangiolar proliferation (Figures 1(a) and 1(b)).
The patient was started on azathioprine. Her liver enzymes
returned to normal values within ﬁve months with an ALT of
30U/L, AST of 29U/L, ALP 36U/L, and a total bilirubin of
0.9mg/dL. A repeat liver biopsy after ﬁfteen months showed
markedimprovementwithonlyminimalportallymphocytes
and no other signiﬁcant histopathological changes. The liver
function test values remained normal at 15 months and at 40
months following the acute episode. The clinicopathological
features of Case 1 are illustrated in Tables 1, 2,a n d3.
Case 2. A 53-years-old woman presented to our liver center
for evaluation of elevated liver enzymes detected at a health
screening fair four months earlier. She had no risk factors for
viral hepatitis, no family history of liver disease, and denied
any alcohol consumption. Although she was initially asymp-
tomatic, she developed right upper quadrant abdominal
pain, fatigue, and lower extremity edema by the time of her
presentation. Her medical history was remarkable only for
irritable bowel syndrome. Her medications within the past
year included dicyclomine for abdominal cramps as needed,
an herbal supplement which contains soy protein and black
cohosh for menopausal symptoms, and occasional over the
counter nonsteroidal anti-inﬂammatory drugs (NSAIDs) for
pain. She discontinued these medications on the advice of
her primary care physician. Laboratories showed a total
bilirubin of 2.0mg/dL, ALT 443U/L, AST 478U/L, ALP
188U/L, and an INR of 2.0. Other notable laboratory values
included negative serological evidence of active hepatitis
A, B, and C viral infection, undetectable hepatitis C virus
RNA by PCR, iron 137µg/dL, ferritin 1527ng/mL, negative
hemochromatosis gene analysis, and nonsigniﬁcant cerulo-
plasmin level. Serological tests for antinuclear, antismooth
muscle, antiliver kidney microsomal, and antimitochon-
drial antibodies were negative. An ultrasound demonstrated
patent portal and hepatic veins and a normal appearing liver.
Her liver biopsy was remarkable for centrilobular necrosis
with moderate cholangiolar proliferation and plasma cell
rich interface and lobular hepatitis.
The patient was started on 40mg of prednisone daily.
Liver function test values improved to a total bilirubin of
1.4mg/dL, ALT of 60U/L, AST 50U/L, and ALP 153U/L
after two weeks and normalized after ﬁve weeks of therapy.
The clinicopathological features of Case 2 are illustrated in
Tables 1, 2,a n d4.
3. Application of the NaranjoCausality
Score for Adverse Drug Reactions
The Naranjo causality score for adverse drug reactions [8]
was applied to the cases described here. As shown in Table 5,
thecurrentcasestudiesindividuallyachievedaNaranjoscore
of 3 and were both categorized as “possible adverse drug
reaction”, in a scale encompassing a minimum score of zero,
or “doubtful adverse drug reaction” to a maximum score of
≥9 , or “deﬁnite adverse drug reaction.”
4. ApplicationoftheHennes-SimpliﬁedCriteria
forDiagnosisofAutoimmuneHepatitis(AIH)
While the current case studies showed histopathological
features of autoimmune hepatitis, neither fulﬁlled a diag-
nosis of “probable AIH” or “deﬁnite AIH” based on the
Hennes simpliﬁed criteria for diagnosis of AIH [10]. Brieﬂy,
Case 1 h a da nA N At i t e ro fu pt o1:8 0( s c o r e2 ) ,n o
available immunoglobulin titers (no score), a liver histology
compatible with AIH (score 1), and absence of viral hepatitis
( s c o r e2 ) ,wi t hat o t a ls c o r eo f5 .C a s e2 had a score of 1-0-1-2
= 4, on a scale where a score of ≥6 was designated “probable
AIH”, and ≥7 as “deﬁnite AIH.”
5. Discussion
Botanical dietary supplements are used commonly in the
United States and are generally perceived to be safe [11].
In one study, nearly one half of persons reported use
of at least one agent to their primary provider [12]. A
major diﬃculty in studying black cohosh is uncertainty
regarding the composition of the various black cohosh
products.Blackcohoshitselfcontainsanumberofsecondary
compounds including phenolic derivatives and triterpene
glycosides [13]. Phytoestrogens were postulated to play a
role in black cohosh binding to estrogen receptors, but
the presence of these compounds is controversial. In one
study, chromatographic analysis of 11 commercial blackCase Reports in Medicine 3
Table 1: Current case studies: clinical features and medications.
Clinical features Case 1 Case 2
Age (years) 42 53
Gender Female Female
Signs Mild icterus Increased LFTs
Symptoms Progressive malaise, nausea RUQ
∗∗ abdominal pain, fatigue
Vomiting, dizziness Lower extremity edema
Stigmata of CLD Absent Absent
Medications Black cohosh OTC with soy and black cohosh
Indication Menopausal symptoms Menopausal symptoms
Dose Not speciﬁed Not speciﬁed
Duration 6 months 8 months
Other medications Levothyroxine Dicyclomine; NSAID
Indication Hyperthyroidism GI cramps; pain
Dose 0.05mg daily Not speciﬁed
Duration Chronic As needed
LFTs: Liver function tests.
RUQ: Right upper quadrant.
CLD: Chronic liver disease.
OTC: Over the counter drug.
NSAID: Nonsteroidal anti-inﬂammatory drug.
Table 2: Current case studies: past medical history, serological tests, and other pertinent laboratory data.
Case 1 Case 2
Past medical history Viral or non-viral hepatitis Absent Absent
Alcohol consumption Absent Absent
Serological tests
Anti-HAV IgM Absent Absent
Anti-HAV total Absent Absent
HBV surface antigen Absent Absent
Anti-HBV core Absent Absent
Anti-HBV surface Absent Absent
Anti-HCV Absent Absent
EBV Ca IgM Absent Absent
EBV Ca IgG Absent Absent
EBV Na IgG Absent Absent
EBV IgG Absent Absent
Anti-CMV IgM Absent Absent
HCV RNA PCR Negative Negative
Other laboratory values
Iron (normal: 50–70µg/dL for women) 169µg/dL 137µg/dL
Ferritin (normal: 15–200ng/mL in women) 642ng/mL 1527ng/mL
HFE gene analysis Negative Negative
Ceruloplasmin Normal Normal
cohosh products showed that three were actually Asian Actea
species [13]. An analysis of the remaining eight products
found variability in the composition of triterpene glycosides
and phenolic constituents. More importantly, not a single
product contained a phytoestrogen. Thus, the mechanism by
which black cohosh might impact on alleviating menopausal
symptoms is not well understood. Other possibilities include
binding to yet-to-be-deﬁned receptors or eﬀects on the
central nervous system [14]. Whether black cohosh is
eﬀective in controlling vasomotor symptoms of menopause
is controversial as well. The American College of Obstetrics
and Gynecology included black cohosh as a possible remedy
for the vasomotor symptoms of menopause [15]. A large
randomized-blinded trial of one-year duration found no
diﬀerence between black cohosh and placebo in controlling
vasomotor symptoms [16]. Moreover, a recent review did
not recommend long-term use due to the absence of safety
evaluation [17].
There are a growing number of case reports of hep-
atotoxicity in patients taking black cohosh (Table 6)[ 1–
7]. Most described acute hepatic necrosis, although three
articles of them detailed a case with clinical features of4 Case Reports in Medicine
Table 3: Duration of Illness and black cohosh use, liver function tests, autoimmune markers, histology, and treatment.
Case 1
Time of use to illness: 6m o ∗ ∗↓
Time of use to discontinuation: 6m o ∗ ∗↓
Time of presentation to the liver clinic
∗ ∗↓
Duration of illness in months 24 7 1 2 1 5 4 0
Treatment — Prednisone Azathioprine — — —
Liver function tests (normal)
Total bilirubin (0.8–1.2mg/dL) 3.1 1.4 1.8 0.9 1.0 0.8
ALT (5–40U/L) 1457 334 321 30 39 37
AST (10–40U/L) 696 229 236 29 37 33
ALP (30–120U/L) 94 68 66 36 38 37
INR (0.8–1.2) 1.2 1.17 — 0.95 — 0.92
Autoimmune antibodies
Antinuclear antibody 1 : 40 1 : 20 — — — —
Antismooth muscle antibody 1 : 80 — — — — —
Liver biopsy ﬁndings — Acute hepatitis Chronic hepatitis — Biopsy at 15mo.
Lobular
Necrosis — Central & portal — — Absent
Inﬁltrates — Mixed with eosinophils Plasmacytic — Absent
Other ﬁndings — Disarray, ballooning Apoptosis — No signiﬁcant abnormality
Portal and periportal
Cholangiolar proliferation — Moderate Moderate — Absent
Inﬁltrate severity — Moderate Moderate — Minimal
Inﬁltrate predominant type — Mixed with eosinophils Plasmacytic — Lymphocytes
Fibrosis — Fibronecrosis Fibronecrosis — Absent
autoimmune hepatitis after black cohosh use [1, 2, 5]. The
clinicopathological features of the cases in the current series
have a fascinating combination of ﬁndings. Both patients
presented with an acute hepatitis displaying prominent
centrilobular necrosis consistent with severe drug-induced
liver injury. While autoantibodies were low titer or absent,
thehistologyshowedcharacteristicsofautoimmunehepatitis
with a plasma cell rich interface and lobular hepatitis.
In addition, both patients responded to corticosteroids,
supporting an immune mediated component to the liver
injury.
Determining the risk of black cohosh hepatotoxicity
is further complicated by variability in both dosage and
number of other botanical herbal supplements contained
in some preparations. As an example, in the case reported
by Lontos [4], the preparation of black cohosh included
4 other botanicals: ground ivy, golden seal, gingko, and
oat seeds. While liver injury remains unreported with the
use of the last 3 botanicals, ground ivy contains a known
hepatotoxin, pulegone. This case culminated in liver failure
despite discontinuation of the herbal supplement [4].
Drug interactions might further potentiate negative
outcomes resulting from hepatoxicity due to herbal supple-
ments.Thatsubjectsin3of5reportedcasesofautoimmune-
like liver injury following consumption of black cohosh
(Table 6) also had concomitant intake of synthetic thyroid
hormone, levothyroxine, merits attention [2, 5]. Herbal
supplements such as venencapsan and black cohosh, and
prescription drugs speciﬁcally rosiglitazone, ritonavir, and
valproic acid, have had reported drug interactions with
levothyroxine [1, 9, 18–22].
A 2008 review by Mahady assigned all known case
reports of black cohosh-induced liver injury under the
category of “possible causality” [9]. As earlier stated, both
cases of the current study were also assigned “possible
causality” by Naranjo scale [8]. Although no clinical or
animal pharmacokinetic or toxicological information were
identiﬁed in the Mahady review, it led to the inclusion of a
cautionary statement on black cohosh products which was
not previously required [9]. Despite such development, the
use of botanical dietary supplements is generally viewed
by the public as safe [11]. Providers are encouraged to
screen patients about their consumption of botanical herbal
supplements and to assess for any evidence of liver injury
[1]. Timely discontinuation of hepatotoxic agents and, in
somecases,earlyinitiationofimmunotherapymightprevent
signiﬁcant liver injury or could even be life saving [4].
The validity of reported cases of liver injury due to black
cohosh illustrated in Table 6 has been disputed. Concerns
that led to this uncertainty included cases in which the
timing of liver injury occurred at a relatively short interval
following exposure to black cohosh [2, 6, 7], presence of
comorbidities such as cholelithhiasis [6] or concomittant use
of drugs other than black cohosh that could have potentiallyCase Reports in Medicine 5
Table 4: Duration of Illness and black cohosh use, liver function tests, autoimmune markers and histology.
Case 2
Time of use to illness: 8 months
∗ ∗ ↓
Time of use to discontinuation: 8 months
∗ ∗ ↓
Time of presentation to liver clinic
∗ ∗ ↓
Duration in months 44 . 5 5
Treatment Prednisone
Liver function tests (normal values)
Total bilirubin (0.8–1.2mg/dL) 2.0 1.4 0.6
ALT (5–40U/L) 443 60 30
AST (10–40U/L) 478 50 38
ALP (30–120U/L) 188 153 98
INR (0.8–1.2) 2.0 — 1.3
Autoimmune antibodies
Anti-nuclear antibody Negative 1 : 20 —
Anti-smooth muscle antibody Negative — —
Liver biopsy ﬁndings ——
Lobular
Necrosis Central — —
Inﬁltrates Plasmacytic — —
Other ﬁndings Disarray, apoptosis — —
Portal and periportal
Cholangiolar proliferation Moderate — —
Inﬁltrate severity Moderate — —
Inﬁltrate predominant type Plasmacytic — —
Fibrosis Fibronecrosis — —
Table 5: Naranjo [8] Causality Scale for Adverse Drug Reactions.
Question/Scoring-Yes/No/Do not know or unavailable Case 1 Case 2
1 Are there previous conclusive reports on this reaction? 1/0/0 0 0
2 Did the adverse event appear after the suspected drug was
given? 2/−1/0 2 2
3 Did the adverse reaction improve when the drug was
discontinued or a speciﬁc antagonist was given? 1/0/0 1 1
4 Did the adverse reaction appear when the drug was
readministered? 2/−1/0 0 0
5 Are there alternative causes that could have caused the reaction?
−1/2/0
−1 −1
6 Did the reaction reappear when a placebo was given? −1/1/0 0 0
7 Was the drug detected in any body ﬂuid in toxic concentrations?
1/0/0 0 0
8 Was the reaction more severe when the dose was increased/
increasing, or less severe when the dose was decreased? 1/0/0 1 1
9 Did the patient have a similar reaction to the same or similar
drugs in any previous exposure? 1/0/0 0 0
Total score 3 3
Scoring: >9 : deﬁnite adverse drug reaction (ADR).
5–8 : probable ADR.
1–4 : possible ADR.
0 : doubtful ADR.6 Case Reports in Medicine
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triggered the adverse drug reaction [3, 4, 7], or the notion
that some of the reported cases [2], including Case 1 of the
current study (also reported by Mahady [23]), were indeed
examples of autoimmune hepatitis rather than adverse drug
reactions. Nonetheless, application of the Naranjo causality
score to these case reports found possible cause for adverse
drug reaction [8]. Further, autoimmune hepatitis is one
of the known outcomes of drug-induced liver injury. The
immune mechanism is precipitated by a drug or a metabolite
acting as a hapten covalently binding to host cellular protein,
converting into an immunogen [24] and thereby eliciting an
autoimmune response. Outcomes illustrating an association
of chronic hepatitis with autoimmune features developing
following the use of the botanical supplement black cohosh
need to be emphasized.
6. Conclusion
Here we described two cases of liver injury following the
use of black cohosh characterized by chronic hepatitis with
centrilobular necrosis and an interface activity dominated
by plasma cells. While the histopathology in both cases was
compatible with autoimmune hepatitis, clinical evidence for
an autoimmune etiology was lacking. Nonetheless both cases
improved upon withdrawal of the drug and immunosup-
pressive therapy, indicating that there was at least in part a
drug-induced immunological basis to the liver injury.
The current case studies, and three other published
cases of liver injury following the use of black cohosh,
share similar histological characteristics [1, 2, 5]. Hepatic
manifestations following the use of black cohosh should
therefore be added to the list of diﬀerential diagnoses of
hepatic necrosis culminating in chronic hepatitis mimicking
autoimmune hepatitis.
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